Supernus Pharmaceuticals Inc (SUPN)

Currency in USD
44.32
-0.11(-0.25%)
Closed·
43.47-0.85(-1.92%)
·
SUPN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SUPN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
43.8444.68
52 wk Range
29.1645.60
Key Statistics
Prev. Close
44.43
Open
44.19
Day's Range
43.84-44.68
52 wk Range
29.16-45.6
Volume
372.84K
Average Volume (3m)
796.73K
1-Year Change
27.05%
Book Value / Share
19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SUPN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
43.00
Downside
-2.98%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy

Supernus Pharmaceuticals Inc Company Profile

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.

Employees
674

Supernus Pharmaceuticals Inc Earnings Call Summary for Q2/2025

  • Q2 revenue of $165M beat forecast by 7.26%, but EPS of $0.40 missed by 16.67%; shares up 1.3% after hours to $37.05
  • Full-year revenue guidance raised to $670-$700M; strong growth in KELBRE and GOCOVRI products noted
  • Cash position of $523M as of June 30; healthy debt-to-equity ratio of 0.03 and current ratio of 2.44
  • CEO: '2025 represents a turning point for Supernus and the beginning of a new phase of accelerated growth'
  • Focus on CNS and women's health markets; potential M&A opportunities highlighted by management
Last Updated: 05/08/2025, 22:42
Read Full Transcript

Compare SUPN to Peers and Sector

Metrics to compare
SUPN
Peers
Sector
Relationship
P/E Ratio
38.6x−5.9x−0.5x
PEG Ratio
0.03−0.180.00
Price/Book
2.3x1.8x2.6x
Price / LTM Sales
3.7x2.8x3.3x
Upside (Analyst Target)
1.5%67.6%38.7%
Fair Value Upside
Unlock13.9%5.0%Unlock

Analyst Ratings

3 Buy
2 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 43.00
(-2.98% Downside)

Earnings

Latest Release
Aug 05, 2025
EPS / Forecast
0.40 / 0.48
Revenue / Forecast
165.50M / 154.30M
EPS Revisions
Last 90 days

SUPN Income Statement

People Also Watch

68.60
NXT
+1.49%
18.26
SRPT
+1.11%
178.60
ALAB
+2.56%
147.49
CAH
+0.99%
625.46
GEV
+3.84%

FAQ

What Stock Exchange Does Supernus Trade On?

Supernus is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Supernus?

The stock symbol for Supernus is "SUPN."

What Is the Supernus Market Cap?

As of today, Supernus market cap is 2.48B.

What Is Supernus's Earnings Per Share (TTM)?

The Supernus EPS (TTM) is 1.16.

When Is the Next Supernus Earnings Date?

Supernus will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is SUPN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Supernus Stock Split?

Supernus has split 0 times.

How Many Employees Does Supernus Have?

Supernus has 674 employees.

What is the current trading status of Supernus (SUPN)?

As of 26 Aug 2025, Supernus (SUPN) is trading at a price of 44.32, with a previous close of 44.43. The stock has fluctuated within a day range of 43.84 to 44.68, while its 52-week range spans from 29.16 to 45.60.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.